Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE1 | P24864 | 8/20 | 0.54 |
| ▸ | CDK2 | P24941 | 8/20 | 0.54 |
| ▸ | CDK4 | P11802 | 5/20 | 0.54 |
| ▸ | CDK1 | P06493 | 4/20 | 0.54 |
| ▸ | CCNE2 | O96020 | 7/20 | 0.52 |
| ▸ | CCND1 | P24385 | 4/20 | 0.52 |
| ▸ | CCNB2 | O95067 | 3/20 | 0.52 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.52 |
| ▸ | CCNB3 | Q8WWL7 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | XBP1 | P17861 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7507718 | 1.00 | CCNE1 (0.54) | CCNE1CDK2CDK4CDK1CCNE2 | |
| SCHEMBL5724940 | 1.00 | CCNE1 (0.54) | CCNE1CDK2CDK4CDK1CCNE2 | |
| SCHEMBL2666853 | 0.84 | MAPT (0.41) | CCNE1CDK2CDK4CDK1CCNE2 | |
| SCHEMBL12499239 | 0.80 | HDAC1 (0.47) | MAPTLMNAHTTALDH1A1CA12 | |
| SCHEMBL16912896 | 0.79 | CA12 (0.45) | MAPTLMNAHTTALDH1A1CA12 | |
| SCHEMBL998679 | 0.79 | MAPT (0.42) | MAPTLMNAHTTALDH1A1HPGD | |
| SCHEMBL998681 | 0.79 | MAPT (0.42) | MAPTLMNAHTTALDH1A1HPGD | |
| SCHEMBL25961406 | 0.78 | CA12 (0.44) | MAPTLMNAHTTALDH1A1CA12 | |
| SCHEMBL16808671 | 0.78 | CA12 (0.48) | MAPTLMNAHTTALDH1A1SMN1; SMN2 | |
| SCHEMBL12681711 | 0.78 | SMN1; SMN2 (0.51) | MAPTLMNAHTTALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020165259-A1 | Carbon substituted aminothiazole inhibitors of cyclin dependent kinases | RAWLINS DAVID B (US) | 2002-11-07 | — | — | US | claimed |
| EP-1087951-A4 | CARBON SUBSTITUTED AMINOTHIAZOLE INHIBITORS OF CYCLIN DEPENDENT KINASES | BRISTOL MYERS SQUIBB CO (US) | 2002-08-14 | — | — | EP | claimed |
| EP-1087951-A1 | CARBON SUBSTITUTED AMINOTHIAZOLE INHIBITORS OF CYCLIN DEPENDENT KINASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-04-04 | — | — | EP | claimed |
| WO-1999065884-A1 | CARBON SUBSTITUTED AMINOTHIAZOLE INHIBITORS OF CYCLIN DEPENDENT KINASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-12-23 | — | — | WO | claimed |
| EP-1087951-B9 | CARBON SUBSTITUTED AMINOTHIAZOLE INHIBITORS OF CYCLIN DEPENDENT KINASES | BRISTOL MYERS SQUIBB CO (US) | 2006-09-13 | — | — | EP | disclosed |
| EP-1087951-B1 | CARBON SUBSTITUTED AMINOTHIAZOLE INHIBITORS OF CYCLIN DEPENDENT KINASES | BRISTOL MYERS SQUIBB CO (US) | 2005-02-09 | — | — | EP | disclosed |
| US-6720347-B2 | SUCH AS ETHYL-3-((E)-2-ACETAMIDO-THIAZOL-5-YL)-ACRYLATE FOR TREATMENT OF CANCER, PROLIFERATIVE DISEASES, INFLAMMATION, AND ARTHRITIS | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-13 | — | — | US | disclosed |
| US-20020165259-A1 | Carbon substituted aminothiazole inhibitors of cyclin dependent kinases | RAWLINS DAVID B (US) | 2002-11-07 | — | — | US | disclosed |
| EP-1087951-A4 | CARBON SUBSTITUTED AMINOTHIAZOLE INHIBITORS OF CYCLIN DEPENDENT KINASES | BRISTOL MYERS SQUIBB CO (US) | 2002-08-14 | — | — | EP | disclosed |
| US-6407124-B1 | ANTICARCINOGENIC, ANTIPROLIFERATIVE, ANTIINFLAMMATORY, AND ANTIARTHRITIC AGENTS; ALZHEIMER*S DISEASE AND CARDIOVASCULAR DISORDER TREATMENT | BRISTOL-MYERS SQUIBB COMPANY | 2002-06-18 | — | — | US | disclosed |
| EP-1087951-A1 | CARBON SUBSTITUTED AMINOTHIAZOLE INHIBITORS OF CYCLIN DEPENDENT KINASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-04-04 | — | — | EP | disclosed |
| WO-1999065884-A1 | CARBON SUBSTITUTED AMINOTHIAZOLE INHIBITORS OF CYCLIN DEPENDENT KINASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020165259-A1 | Carbon substituted aminothiazole inhibitors of cyclin dependent kinases | CCNK, CDK2, CCNL2 | CCNE1 12/4885CDK2 2/4885CDK4 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.